News | June 02, 2023
Evonik launches next-generation peptide for biopharma applications
One thousand times more soluble than L-cystine at neutral pH
One thousand times more soluble than L-cystine at neutral pH
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The target boundary includes biogenic land?related emissions and removals from bioenergy feedstock
The drug exhibited greater treatment persistence and control of moderate-to-severe PsO symptoms compared to secukinumab and ixekizumab
For the treatment of Superficial Femoral Artery
Subscribe To Our Newsletter & Stay Updated
